Targeting CD30 in patients with Hodgkin lymphoma Journal Article
| Authors: | Kumar, A.; Pileri, S.; Younes, A.; Engert, A. |
| Article Title: | Targeting CD30 in patients with Hodgkin lymphoma |
| Abstract: | The introduction of multi-agent chemotherapy for the treatment of Hodgkin lymphoma is one of the major breakthroughs in clinical oncology. Treatment with multi-agent chemotherapy and improved radiation methods has significantly improved the chance of curing these patients from less than 5% in 1963 to about 80% at present. However, there is still a substantial need to improve current treatment approaches particularly for elderly patients or those with relapsed and refractory disease. Cured patients unfortunately are at high risk for late side effects including second malignancies, cardiac toxicity, infertility, and fatigue. Thus, there is a clear need for new and safer drugs that are more selective in targeting the malignant Hodgkin and Reed-Sternberg (HRS) cells in this disease while sparing normal tissues. © Springer Nature Switzerland AG 2020. |
| Keywords: | autologous stem cell transplantation; hodgkin lymphoma; anaplastic large cell lymphoma; brentuximab vedotin; john cunningham virus |
| Journal Title: | Hematologic Malignancies |
| ISSN: | 2197-9766 |
| Publisher: | Springer |
| Date Published: | 2020-01-01 |
| Start Page: | 381 |
| End Page: | 393 |
| Language: | English |
| DOI: | 10.1007/978-3-030-32482-7_22 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Chapter 22 in "Hodgkin Lymphoma - A Comprehensive Review. 3rd ed" (ISBN: 978-3-030-32481-0) -- Export Date: 1 June 2020 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work